High-dose vitamin C for advanced plasma cell disorders
Part of Cancer clinical trials.
This trial tests whether high doses of vitamin C, given with standard chemotherapy, can help people with multiple myeloma or related plasma cell disorders who have already tried several treatments. It includes a stem cell transplant step, so you must have stored stem cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have myeloma or a similar plasma cell disorder and have tried 3 or more treatments (like proteasome inhibitors, lenalidomide, or daratumumab) that stopped working within the last 6 months.
- You are 18 years or older.
- You have stored at least 1 million CD34 stem cells per kilogram of your weight.
- Your disease is measurable by blood or urine tests (for example, M-protein in blood or urine, or high free light chains).
- Your heart, lungs, kidneys, and liver are working well enough (your doctor will check this with tests).
- You have an ECOG performance status of 0-2 (able to care for yourself and do light activities), or a higher status only due to bone pain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether HDP-101 is safe and can potentially help adults with multiple myeloma that has come back or didn’t respond to standard treatments. It focuses on people who have already tried key myeloma medicines and still have measurable disease.
This trial tests adding high-dose vitamin C (ascorbate) to the standard two-drug treatment (azacitidine and venetoclax) for people with newly diagnosed acute myeloid leukemia who are not candidates for intensive chemo. The goal is to see if the vitamin C makes the standard treatment work better and helps control the leukemia.
This trial tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy helps treat lymphomas that have come back or not responded, as well as two related blood disorders (CCUS and CMML). The goal is to see if the vitamin C makes the chemo work better.
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
This trial tests a new combination treatment for people who have just been diagnosed with primary plasma cell leukemia. The treatment includes a study drug called CM336 along with other cancer-fighting medicines. It aims to see if this combination helps control the disease.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
Hear when a new Plasma Cell Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.